Key Highlights

  • Definium Therapeutics reported its second positive Phase 3 GAD study for DT120 ODT.
  • The Panorama trial met the Week 12 HAM-A primary endpoint at the 100 µg dose with a 5.1-point placebo-adjusted improvement.
  • The drug showed rapid onset by Day 2, with no drug-related serious adverse events.
  • The results support a broader anxiety and depression regulatory package after prior positive Voyage and Emerge readouts.

Definium Therapeutics, Inc. (NASDAQ: DFTX) reported its second positive Phase 3 GAD study for DT120 ODT, with the Panorama trial meeting the Week 12 HAM-A primary endpoint at the 100 µg dose with a 5.1-point placebo-adjusted improvement and rapid onset by Day 2.

What Happened

Safety remained generally well tolerated with no drug-related serious adverse events, supporting a broader anxiety and depression regulatory package after prior positive Voyage and Emerge readouts.

Market Reaction

The disclosed information does not include stock price or trading data for Definium Therapeutics following the Panorama trial results.

Outlook

Continued progress toward a broader regulatory package spanning anxiety and depression indications, building on the positive Voyage, Emerge, and Panorama trial results, represents the next relevant development for DT120 ODT.